Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

Royalty Pharma announced today that, pursuant to a collaboration with Aisling Capital and Clarus Ventures, it has sold to Aisling and Clarus approximately 20% of the royalty interest in ibrutinib it recently acquired from Quest Diagnostics (NYSE: DGX ) for a pro rata percentage of the $485 million Royalty